GeneDx Stock Plummets 49% Following Q1 Earnings Miss and Guidance Cut

In a move reflecting the growing disconnect between growth narratives and financial reality in the genomic testing sector, GeneDx Holdings shares suffered a massive collapse. The stock price plummeted by $33.42, or 49%, in a single trading session following the release of its Q1 2026 financial results. According to reports, the company's net loss increased tenfold during the quarter, triggering a drastic reduction in full-year guidance and wiping out over $900 million in market capitalization.

This sharp decline comes as the broader healthcare and diagnostics sector faces mounting operational pressures. Peer comparisons highlight these industry headwinds; for instance, Invitae Corp, a direct competitor in genetic testing, previously faced similar financial distress leading to significant restructuring per Reuters reports. Market data indicates this drop represents the most significant single-day loss for the stock, underscoring a pivot in investor sentiment regarding the firm's path to profitability.

Traders should monitor technical support levels following this historic sell-off, as the stock remains at depressed levels relative to its May 2026 closes. Looking ahead at the economic calendar, while sector-specific catalysts are sparse, the speech by Fed's Kashkari on May 29, 2026, will be a key event to watch for its potential impact on risk appetite for loss-making mid-cap growth stocks.